Dr. McIntyre on Frontline Eribulin in HER2-Negative MBC
December 13th 2013Kristi McIntyre, MD, from Texas Oncology, discusses the results of a phase II, multicenter, single-arm study that studies eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.
Read More